Cerus Corporation

CERS Healthcare Medical Devices

In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.

2.20 0.06 −2.65%
Market cap
$455.5M
P/E
0.0×
Fwd P/E
−81.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(27.41%) (25.65%) (15.34%) (10.69%)
Piotroski F-Score
5 5 5 5
ROA
(7.89%) (7.39%) (4.45%) (3.24%)
ROIC
(8.65%) (8.22%) (2.74%) (1.27%)
Return on Tangible Assets
(18.72%) (18.88%) (12.37%) (8.38%)
Average Days of Receivables
48.09 47.42 43.71 45.59
Free Cash Flow per Share
0.00 0.01 (0.01) (0.01)
Free Cash Flow
0.17 1.11 (1.22) (1.83)
Other line items

Show all line items

Columns are period end dates